TY  - GEN
AU  - Romera,Alvaro
AU  - Peredpaya,Sergiy
AU  - Shparyk,Yaroslav
AU  - Bondarenko,Igor
AU  - Mendonça Bariani,Giovanni
AU  - Abdalla,Kathia Cristina
AU  - Roca,Enrique
AU  - Franke,Fábio
AU  - Melo Cruz,Felipe
AU  - Ramesh,Anita
AU  - Ostwal,Vikas
AU  - Shah,Pradeep
AU  - Rahuman,Sajeed Abdul
AU  - Paravisini,Alexandra
AU  - Huerga,Camino
AU  - Del Campo García,Ana
AU  - Millán,Susana
TI  - Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial
SN  - 2468-1253
PY  - 2019///0528
KW  - Adult
KW  - Aged
KW  - Antibodies
KW  - blood
KW  - Antineoplastic Agents, Immunological
KW  - adverse effects
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Area Under Curve
KW  - Bevacizumab
KW  - Biosimilar Pharmaceuticals
KW  - Camptothecin
KW  - analogs & derivatives
KW  - Colorectal Neoplasms
KW  - drug therapy
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - Intention to Treat Analysis
KW  - Leucovorin
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Organoplatinum Compounds
KW  - Progression-Free Survival
KW  - Therapeutic Equivalency
N1  - Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S2468-1253(18)30269-3
ER  -